Enochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"

Enochian Biosciences emerged from the ashes of Dandrit and is currently valued at $238 million because of a preclinical, potential cure for HIV and a researcher that management has frequently named a "genius". But scientists doubt the company.

René Sindlev turned troubled biotech Dandrit into a new company by the name of Enochian Biosiences and acquired the rights to a potential cure for HIV. Scientists now question what the company really has in its pipeline. | Photo: David Leth Williams / STF / Ritzau Scanpix

In 2017, Pandora billionaire René Sindlev took matters into his own hands. He had been a key shareholder of the cancer biotech Dandrit for years, but apparently he had had enough: He took the reins and put Dandrit to rest. The company had been working on a failed cancer vaccine, MCV, which according to Sindlev "couldn't even be given away".

Less than one year later, a small Danish-American biotech company rose from the ashes of the failed cancer biotech.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today